Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 5/20 | 0.49 |
| ▸ | MAOB | P27338 | 10/20 | 0.47 |
| ▸ | MAOA | P21397 | 9/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076400 | 0.78 | MAOB (0.73) | PYCR1MAOBMAOACYP1A2ADRA2A | |
| SCHEMBL10076445 | 0.78 | MAOB (0.73) | PYCR1MAOBMAOACYP1A2ADRA2A | |
| SCHEMBL16795651 | 0.75 | PYCR1 (0.44) | PYCR1MAOBMAOACYP1A2ADRA2A | |
| SCHEMBL10076395 | 0.75 | MAOB (0.48) | PYCR1MAOBMAOACYP1A2ADRA2A | |
| SCHEMBL10076437 | 0.74 | MAOB (0.54) | PYCR1MAOBMAOACYP1A2ADRA2A | |
| SCHEMBL10076413 | 0.74 | MAOB (0.54) | PYCR1MAOBMAOACYP1A2ADRA2A | |
| SCHEMBL12532745 | 0.71 | MAOB (0.46) | PYCR1MAOBMAOACYP1A2ADRA2A | |
| SCHEMBL10076396 | 0.71 | PYCR1 (0.44) | PYCR1MAOBMAOACYP1A2ADRA2A | |
| SCHEMBL14492369 | 0.70 | MAOB (0.66) | MAOBMAOACYP1A2ADRA2AADRA2B | |
| SCHEMBL10076442 | 0.70 | MAOB (0.46) | PYCR1MAOBMAOACYP1A2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | PYCR1 987/4885MAOB 1/4885MAOA 2/4885 |
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | PYCR1 987/4885MAOB 1/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.